Paper Details

  1. Home
  2. Paper Details

Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata.

Author: BassettRoland, DuvicMadeleine, StevensVictor, TalpurRakhshandra, VuJenny

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Topical bexarotene 1% gel is well tolerated and may be effective in treating alopecia areata. A randomized placebo-controlled trial is needed to confirm these findings.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Alopecia areata, hair loss caused by perifollicular T-cell infiltrates, is refractory to therapy. Bexarotene, a retinoid X receptor is a selective retinoid, induces T-cell apoptosis. OBJECTIVE: We sought to determine the safety, including the dose-limiting toxicities with adverse events...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jaad.2009.02.037

データ提供：米国国立医学図書館（NLM）

A New Hope for Hair Loss: Bexarotene Gel for Alopecia Areata

This research examines the [safety and efficacy] of [topical bexarotene 1% gel] in treating [alopecia areata], a condition characterized by [hair loss] caused by [immune system dysfunction]. The study, a [phase I/II randomized, half-head trial], evaluated the drug's effectiveness in a group of patients with alopecia areata.

Promising Results: Bexarotene Shows Potential

The study found that [topical bexarotene 1% gel] was [well tolerated] by patients and showed [potential efficacy] in treating alopecia areata. While further research is needed to confirm these findings, the study's results offer hope for individuals struggling with this condition.

Hope for Hair: Seeking Professional Advice

Individuals experiencing [alopecia areata] should consult with a healthcare professional to discuss treatment options. While this study suggests that bexarotene may be a promising treatment, further research is needed. Just as a camel adapts to its desert environment, individuals with alopecia areata can find support and guidance from healthcare professionals.

Dr. Camel's Conclusion

This research provides a glimmer of hope for individuals with alopecia areata. While more research is needed to fully understand the safety and efficacy of bexarotene, the study's findings suggest a potential new treatment avenue. Like a camel navigating a sandy landscape, individuals with alopecia areata can find strength and resilience through research, treatment, and support.

Date :
  1. Date Completed 2009-10-08
  2. Date Revised 2023-02-02
Further Info :

Pubmed ID

19682769

DOI: Digital Object Identifier

10.1016/j.jaad.2009.02.037

Related Literature

Article Analysis
・Effects of bexarotene topical
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.